Mutations in genes such as TP53, LRP1B, and FGFR2 have been implicated in the pathogenesis and progression of poorly differentiated NSCLC and its small intestinal metastasis, offering insights for personalized treatment strategies through targeted therapies and radiation (17). Here, FGFR2 is linked to non-small cell lung carcinoma.